Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
April 18, 2014, 11:39:40 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 620324
  • Total Topics: 46737
  • Online Today: 254
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: OTHER BREAKTHROUGHS IN HIV SCIENCE  (Read 2186 times)

0 Members and 1 Guest are viewing this topic.

Offline bimazek

  • Member
  • Posts: 781
OTHER BREAKTHROUGHS IN HIV SCIENCE
« on: January 04, 2007, 07:44:53 PM »
OTHER BREAKTHROUGHS IN HIV SCIENCE     
     
Maraviroc remains on track for a new drug in treatment-experienced patients by year-end 2006. The compound blocks entry of HIV virus into cells by binding to the CCR5 co-receptor.

               

Another breakthrough in HIV Science which won the Noble prize in October 2006 by two young scientists
out of Stanford, called RNA interference, RNAi, has emerged as an effective way to block the specific messenger
RNAs in human cells. Using this approach, it has proven possible to block the replication
of HIV-1 in cells using small interfering RNAs targeted to viral sequences or to messenger
RNAs that encode factors critical for virus replication.  What about HIVs ability to mutate?
This problem may be circumvented by simultaneously targeting several essential HIV-1 sequences using RNA interference.

         
         
     
     
Merck has just purchased the rights for PPL-100 HIV protease inhibitor, for $215 million, from the Biotech company,  Ambrilia based in Quebec U.S. as the product moves through trials to a target market launch in 2011.  "This is the breakthrough that will transform our company," said Ambrilia CEO Hans Mader. "This drug can help fight the HIV virus and lengthen lives."    Merck, itself a leading developer of HIV/AIDS drugs, takes over development of Ambrilia's PPL-100 when certain Phase I trials are completed in November. Technically, PPL-100 is an HIV protease inhibitor,
     

A Southern California based biotech company, Immune Response said "With guidelines recommending delayed intervention for newly diagnosed HIV patients based on CD4 and viral load counts, an immune-based therapy like REMUNE® that could possibly delay initiation of antiretroviral therapy would be an important advance in the treatment of HIV."   Also another medicine IR103 for HIV/AIDS studies indicate that a patient's CD4+ count is the
most significant marker of HIV disease progression. An immune based therapy
like IR103 that can impact CD4+ count may well be an enormous contribution
to the current treatment landscape.   an article from this month's issue of
Scientific American called "Peacekeepers of the Immune System" which
details the role of FoxP3+ T Regulatory cells, the same cells our product,
NeuroVax(TM) has been shown to stimulate, HIV/AIDS -- IR103,
HIV/AIDS community are beginning to
understand that the "whole, inactivated" HIV antigen concept -- our
technology -- has not been explored enough either as a therapeutic or
preventive vaccine.




merck: MK-0518, an investigational oral HIV integrase inhibitor   Tolerability of MK-0518 was comparable to placebo plus greater antiretroviral suppression was maintained, in HIV-infected patients who failed antiretroviral therapy and who were resistant to drugs in all three classes Show That Over 90% of Patients Achieve Treatment Goal of Undetectable Viral Load.
Exciting new clinical data demonstrate that 90 to 95 percent HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) and the investigational integrase inhibitor MK-0518 can achieve undetectable levels of HIV


 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.